サマリー

アルツハイマー病治療薬の世界市場 2024-2028
アルツハイマー病治療薬市場は、2023年から2028年にかけて54億1000万米ドルの成長が予測され、予測期間中のCAGRは10.03%で加速すると予測されます。当レポートでは、アルツハイマー病治療薬市場の全体的な分析、市場規模と予測、動向、成長促進要因、課題に加え、約25のベンダーを網羅したベンダー分析も提供しています。
現在の市場シナリオ、最新動向と促進要因、全体的な市場環境に関する最新分析を提供しています。市場は、新規バイオマーカーの入手可能性、研究、開発、アルツハイマー病に対する認識の高まり、治療薬の承認と強力なパイプラインによって牽引されています。
Technavioのアルツハイマー病治療薬市場は以下のように区分されています：
流通チャネル別
- 病院薬局
- 小売薬局
- Eコマース薬局
薬剤クラス別
- コリンエステラーゼ阻害薬
- N-メチル-D-アスパラギン酸受容体拮抗薬
- その他
地域別
- 北米
- 欧州
- アジア
- その他の地域（ROW）
本調査では、今後数年間のアルツハイマー病治療薬市場の成長を促進する主な理由の一つとして、再生療法の出現を挙げている。また、治療薬発見のための資金調達の増加や、高感度診断モダリティの利用可能性は、市場の大きな需要につながるでしょう。
当レポートでは、アルツハイマー病治療薬市場について以下の分野をカバーしています：
- アルツハイマー病治療薬市場のサイジング
- アルツハイマー病治療薬市場予測
- アルツハイマー病治療薬市場産業分析
堅牢なベンダー分析は、クライアントが市場での地位を向上できるように設計されており、これに伴い、本レポートでは、AB Science SA、AbbVie Inc.、AgeneBio Inc.、Biogen Inc.、Cipla Ltd.、Curasia Medilab、Denali Therapeutics Inc.、Eisai Co.Ltd.、Eli Lilly and Co.、Grifols SA、H Lundbeck AS、Johnson and Johnson、Lifecare Neuro Products Ltd.、Lupin Ltd.、Novartis AG、Pfizer Inc.、Psycogen Captab、Solco Healthcare、Teva Pharmaceutical Industries Ltd.、Aurobindo Pharma Ltd.。また、アルツハイマー病治療薬市場分析レポートには、市場成長に影響を与える今後の動向や課題に関する情報も含まれています。これは、企業が戦略を立て、来るべき成長機会をすべて活用するのに役立つものです。
本調査は、業界の主要参加者からのインプットを含め、一次情報と二次情報を客観的に組み合わせて実施しました。本レポートには、主要ベンダーの分析に加え、包括的な市場およびベンダーランドスケープが含まれています。本レポートの詳細については、https://www.technavio.com/report/alzheimers-disease-therapeutics-market-industry-size-analysis をご覧ください。
当出版社では、利益、価格、競争、プロモーションなどの主要パラメータの分析により、複数の情報源からのデータを調査、統合、要約する方法で、市場の詳細なイメージを提示しています。また、主要な業界インフルエンサーを特定することで、市場の様々な側面を提示しています。提示されるデータは包括的で信頼性が高く、一次および二次にわたる広範な調査の結果です。市場調査レポートは、正確な市場成長を予測するために、完全な競争環境と、質的・量的調査を用いた綿密なベンダー選定方法と分析を提供します。

ページTOPに戻る

目次

• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary - Chart on Market Overview
o Exhibit 02: Executive Summary - Data Table on Market Overview
o Exhibit 03: Executive Summary - Chart on Global Market Characteristics
o Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
o Exhibit 05: Executive Summary - Chart on Market Segmentation by Distribution Channel
o Exhibit 06: Executive Summary - Chart on Market Segmentation by Drug Class
o Exhibit 07: Executive Summary - Chart on Incremental Growth
o Exhibit 08: Executive Summary - Data Table on Incremental Growth
o Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2023
o 3.4 Market outlook: Forecast for 2023-2028
o Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
o Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
• 4 Historic Market Size
o 4.1 Global alzheimers disease therapeutics market 2018 - 2022
o Exhibit 18: Historic Market Size - Data Table on global alzheimers disease therapeutics market 2018 - 2022 ($ billion)
o 4.2 Distribution Channel Segment Analysis 2018 - 2022
o Exhibit 19: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ billion)
o 4.3 Drug class Segment Analysis 2018 - 2022
o Exhibit 20: Historic Market Size - Drug class Segment 2018 - 2022 ($ billion)
o 4.4 Geography Segment Analysis 2018 - 2022
o Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
o 4.5 Country Segment Analysis 2018 - 2022
o Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
o 5.7 Market condition
o Exhibit 29: Chart on Market condition - Five forces 2023 and 2028
• 6 Market Segmentation by Distribution Channel
o 6.1 Market segments
o Exhibit 30: Chart on Distribution Channel - Market share 2023-2028 (%)
o Exhibit 31: Data Table on Distribution Channel - Market share 2023-2028 (%)
o 6.2 Comparison by Distribution Channel
o Exhibit 32: Chart on Comparison by Distribution Channel
o Exhibit 33: Data Table on Comparison by Distribution Channel
o 6.3 Hospital pharmacy - Market size and forecast 2023-2028
o Exhibit 34: Chart on Hospital pharmacy - Market size and forecast 2023-2028 ($ billion)
o Exhibit 35: Data Table on Hospital pharmacy - Market size and forecast 2023-2028 ($ billion)
o Exhibit 36: Chart on Hospital pharmacy - Year-over-year growth 2023-2028 (%)
o Exhibit 37: Data Table on Hospital pharmacy - Year-over-year growth 2023-2028 (%)
o 6.4 Retail pharmacy - Market size and forecast 2023-2028
o Exhibit 38: Chart on Retail pharmacy - Market size and forecast 2023-2028 ($ billion)
o Exhibit 39: Data Table on Retail pharmacy - Market size and forecast 2023-2028 ($ billion)
o Exhibit 40: Chart on Retail pharmacy - Year-over-year growth 2023-2028 (%)
o Exhibit 41: Data Table on Retail pharmacy - Year-over-year growth 2023-2028 (%)
o 6.5 E-commerce pharmacy - Market size and forecast 2023-2028
o Exhibit 42: Chart on E-commerce pharmacy - Market size and forecast 2023-2028 ($ billion)
o Exhibit 43: Data Table on E-commerce pharmacy - Market size and forecast 2023-2028 ($ billion)
o Exhibit 44: Chart on E-commerce pharmacy - Year-over-year growth 2023-2028 (%)
o Exhibit 45: Data Table on E-commerce pharmacy - Year-over-year growth 2023-2028 (%)
o 6.6 Market opportunity by Distribution Channel
o Exhibit 46: Market opportunity by Distribution Channel ($ billion)
o Exhibit 47: Data Table on Market opportunity by Distribution Channel ($ billion)
• 7 Market Segmentation by Drug Class
o 7.1 Market segments
o Exhibit 48: Chart on Drug Class - Market share 2023-2028 (%)
o Exhibit 49: Data Table on Drug Class - Market share 2023-2028 (%)
o 7.2 Comparison by Drug Class
o Exhibit 50: Chart on Comparison by Drug Class
o Exhibit 51: Data Table on Comparison by Drug Class
o 7.3 Cholinesterase inhibitors - Market size and forecast 2023-2028
o Exhibit 52: Chart on Cholinesterase inhibitors - Market size and forecast 2023-2028 ($ billion)
o Exhibit 53: Data Table on Cholinesterase inhibitors - Market size and forecast 2023-2028 ($ billion)
o Exhibit 54: Chart on Cholinesterase inhibitors - Year-over-year growth 2023-2028 (%)
o Exhibit 55: Data Table on Cholinesterase inhibitors - Year-over-year growth 2023-2028 (%)
o 7.4 N-methyl-D-aspartate receptor antagonist - Market size and forecast 2023-2028
o Exhibit 56: Chart on N-methyl-D-aspartate receptor antagonist - Market size and forecast 2023-2028 ($ billion)
o Exhibit 57: Data Table on N-methyl-D-aspartate receptor antagonist - Market size and forecast 2023-2028 ($ billion)
o Exhibit 58: Chart on N-methyl-D-aspartate receptor antagonist - Year-over-year growth 2023-2028 (%)
o Exhibit 59: Data Table on N-methyl-D-aspartate receptor antagonist - Year-over-year growth 2023-2028 (%)
o 7.5 Others - Market size and forecast 2023-2028
o Exhibit 60: Chart on Others - Market size and forecast 2023-2028 ($ billion)
o Exhibit 61: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
o Exhibit 62: Chart on Others - Year-over-year growth 2023-2028 (%)
o Exhibit 63: Data Table on Others - Year-over-year growth 2023-2028 (%)
o 7.6 Market opportunity by Drug Class
o Exhibit 64: Market opportunity by Drug Class ($ billion)
o Exhibit 65: Data Table on Market opportunity by Drug Class ($ billion)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 67: Chart on Market share By Geographical Landscape 2023-2028 (%)
o Exhibit 68: Data Table on Market share By Geographical Landscape 2023-2028 (%)
o 9.2 Geographic comparison
o Exhibit 69: Chart on Geographic comparison
o Exhibit 70: Data Table on Geographic comparison
o 9.3 North America - Market size and forecast 2023-2028
o Exhibit 71: Chart on North America - Market size and forecast 2023-2028 ($ billion)
o Exhibit 72: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
o Exhibit 73: Chart on North America - Year-over-year growth 2023-2028 (%)
o Exhibit 74: Data Table on North America - Year-over-year growth 2023-2028 (%)
o 9.4 Europe - Market size and forecast 2023-2028
o Exhibit 75: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
o Exhibit 76: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
o Exhibit 77: Chart on Europe - Year-over-year growth 2023-2028 (%)
o Exhibit 78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
o 9.5 Asia - Market size and forecast 2023-2028
o Exhibit 79: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
o Exhibit 80: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
o Exhibit 81: Chart on Asia - Year-over-year growth 2023-2028 (%)
o Exhibit 82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
o 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
o Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
o Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
o Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
o Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
o 9.7 US - Market size and forecast 2023-2028
o Exhibit 87: Chart on US - Market size and forecast 2023-2028 ($ billion)
o Exhibit 88: Data Table on US - Market size and forecast 2023-2028 ($ billion)
o Exhibit 89: Chart on US - Year-over-year growth 2023-2028 (%)
o Exhibit 90: Data Table on US - Year-over-year growth 2023-2028 (%)
o 9.8 Canada - Market size and forecast 2023-2028
o Exhibit 91: Chart on Canada - Market size and forecast 2023-2028 ($ billion)
o Exhibit 92: Data Table on Canada - Market size and forecast 2023-2028 ($ billion)
o Exhibit 93: Chart on Canada - Year-over-year growth 2023-2028 (%)
o Exhibit 94: Data Table on Canada - Year-over-year growth 2023-2028 (%)
o 9.9 UK - Market size and forecast 2023-2028
o Exhibit 95: Chart on UK - Market size and forecast 2023-2028 ($ billion)
o Exhibit 96: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
o Exhibit 97: Chart on UK - Year-over-year growth 2023-2028 (%)
o Exhibit 98: Data Table on UK - Year-over-year growth 2023-2028 (%)
o 9.10 Germany - Market size and forecast 2023-2028
o Exhibit 99: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
o Exhibit 100: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
o Exhibit 101: Chart on Germany - Year-over-year growth 2023-2028 (%)
o Exhibit 102: Data Table on Germany - Year-over-year growth 2023-2028 (%)
o 9.11 Japan - Market size and forecast 2023-2028
o Exhibit 103: Chart on Japan - Market size and forecast 2023-2028 ($ billion)
o Exhibit 104: Data Table on Japan - Market size and forecast 2023-2028 ($ billion)
o Exhibit 105: Chart on Japan - Year-over-year growth 2023-2028 (%)
o Exhibit 106: Data Table on Japan - Year-over-year growth 2023-2028 (%)
o 9.12 Market opportunity By Geographical Landscape
o Exhibit 107: Market opportunity By Geographical Landscape ($ billion)
o Exhibit 108: Data Tables on Market opportunity By Geographical Landscape ($ billion)
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 109: Impact of drivers and challenges in 2023 and 2028
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 111: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 112: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 113: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 114: Matrix on vendor position and classification
o 12.3 AB Science SA
o Exhibit 115: AB Science SA - Overview
o Exhibit 116: AB Science SA - Product / Service
o Exhibit 117: AB Science SA - Key offerings
o 12.4 AbbVie Inc.
o Exhibit 118: AbbVie Inc. - Overview
o Exhibit 119: AbbVie Inc. - Product / Service
o Exhibit 120: AbbVie Inc. - Key news
o Exhibit 121: AbbVie Inc. - Key offerings
o 12.5 AgeneBio Inc.
o Exhibit 122: AgeneBio Inc. - Overview
o Exhibit 123: AgeneBio Inc. - Product / Service
o Exhibit 124: AgeneBio Inc. - Key offerings
o 12.6 Aurobindo Pharma Ltd.
o Exhibit 125: Aurobindo Pharma Ltd. - Overview
o Exhibit 126: Aurobindo Pharma Ltd. - Product / Service
o Exhibit 127: Aurobindo Pharma Ltd. - Key offerings
o 12.7 Cipla Ltd.
o Exhibit 128: Cipla Ltd. - Overview
o Exhibit 129: Cipla Ltd. - Business segments
o Exhibit 130: Cipla Ltd. - Key news
o Exhibit 131: Cipla Ltd. - Key offerings
o Exhibit 132: Cipla Ltd. - Segment focus
o 12.8 Eisai Co. Ltd.
o Exhibit 133: Eisai Co. Ltd. - Overview
o Exhibit 134: Eisai Co. Ltd. - Business segments
o Exhibit 135: Eisai Co. Ltd. - Key offerings
o Exhibit 136: Eisai Co. Ltd. - Segment focus
o 12.9 Eli Lilly and Co.
o Exhibit 137: Eli Lilly and Co. - Overview
o Exhibit 138: Eli Lilly and Co. - Product / Service
o Exhibit 139: Eli Lilly and Co. - Key news
o Exhibit 140: Eli Lilly and Co. - Key offerings
o 12.10 Grifols SA
o Exhibit 141: Grifols SA - Overview
o Exhibit 142: Grifols SA - Business segments
o Exhibit 143: Grifols SA - Key offerings
o Exhibit 144: Grifols SA - Segment focus
o 12.11 H Lundbeck AS
o Exhibit 145: H Lundbeck AS - Overview
o Exhibit 146: H Lundbeck AS - Product / Service
o Exhibit 147: H Lundbeck AS - Key offerings
o 12.12 Johnson and Johnson
o Exhibit 148: Johnson and Johnson - Overview
o Exhibit 149: Johnson and Johnson - Business segments
o Exhibit 150: Johnson and Johnson - Key news
o Exhibit 151: Johnson and Johnson - Key offerings
o Exhibit 152: Johnson and Johnson - Segment focus
o 12.13 Lupin Ltd.
o Exhibit 153: Lupin Ltd. - Overview
o Exhibit 154: Lupin Ltd. - Product / Service
o Exhibit 155: Lupin Ltd. - Key news
o Exhibit 156: Lupin Ltd. - Key offerings
o 12.14 Novartis AG
o Exhibit 157: Novartis AG - Overview
o Exhibit 158: Novartis AG - Business segments
o Exhibit 159: Novartis AG - Key offerings
o Exhibit 160: Novartis AG - Segment focus
o 12.15 Pfizer Inc.
o Exhibit 161: Pfizer Inc. - Overview
o Exhibit 162: Pfizer Inc. - Product / Service
o Exhibit 163: Pfizer Inc. - Key news
o Exhibit 164: Pfizer Inc. - Key offerings
o 12.16 Solco Healthcare
o Exhibit 165: Solco Healthcare - Overview
o Exhibit 166: Solco Healthcare - Key offerings
o 12.17 Teva Pharmaceutical Industries Ltd.
o Exhibit 167: Teva Pharmaceutical Industries Ltd. - Overview
o Exhibit 168: Teva Pharmaceutical Industries Ltd. - Business segments
o Exhibit 169: Teva Pharmaceutical Industries Ltd. - Key news
o Exhibit 170: Teva Pharmaceutical Industries Ltd. - Key offerings
o Exhibit 171: Teva Pharmaceutical Industries Ltd. - Segment focus
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 172: Inclusions checklist
o Exhibit 173: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 174: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 175: Research methodology
o Exhibit 176: Validation techniques employed for market sizing
o Exhibit 177: Information sources
o 13.5 List of abbreviations
o Exhibit 178: List of abbreviations


Exhibits:
Exhibits1: Executive Summary - Chart on Market Overview
Exhibits2: Executive Summary - Data Table on Market Overview
Exhibits3: Executive Summary - Chart on Global Market Characteristics
Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits5: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibits6: Executive Summary - Chart on Market Segmentation by Drug Class
Exhibits7: Executive Summary - Chart on Incremental Growth
Exhibits8: Executive Summary - Data Table on Incremental Growth
Exhibits9: Executive Summary - Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
Exhibits15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
Exhibits16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits18: Historic Market Size - Data Table on global alzheimers disease therapeutics market 2018 - 2022 ($ billion)
Exhibits19: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ billion)
Exhibits20: Historic Market Size - Drug class Segment 2018 - 2022 ($ billion)
Exhibits21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
Exhibits22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)
Exhibits23: Five forces analysis - Comparison between 2023 and 2028
Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
Exhibits25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
Exhibits26: Threat of new entrants - Impact of key factors in 2023 and 2028
Exhibits27: Threat of substitutes - Impact of key factors in 2023 and 2028
Exhibits28: Threat of rivalry - Impact of key factors in 2023 and 2028
Exhibits29: Chart on Market condition - Five forces 2023 and 2028
Exhibits30: Chart on Distribution Channel - Market share 2023-2028 (%)
Exhibits31: Data Table on Distribution Channel - Market share 2023-2028 (%)
Exhibits32: Chart on Comparison by Distribution Channel
Exhibits33: Data Table on Comparison by Distribution Channel
Exhibits34: Chart on Hospital pharmacy - Market size and forecast 2023-2028 ($ billion)
Exhibits35: Data Table on Hospital pharmacy - Market size and forecast 2023-2028 ($ billion)
Exhibits36: Chart on Hospital pharmacy - Year-over-year growth 2023-2028 (%)
Exhibits37: Data Table on Hospital pharmacy - Year-over-year growth 2023-2028 (%)
Exhibits38: Chart on Retail pharmacy - Market size and forecast 2023-2028 ($ billion)
Exhibits39: Data Table on Retail pharmacy - Market size and forecast 2023-2028 ($ billion)
Exhibits40: Chart on Retail pharmacy - Year-over-year growth 2023-2028 (%)
Exhibits41: Data Table on Retail pharmacy - Year-over-year growth 2023-2028 (%)
Exhibits42: Chart on E-commerce pharmacy - Market size and forecast 2023-2028 ($ billion)
Exhibits43: Data Table on E-commerce pharmacy - Market size and forecast 2023-2028 ($ billion)
Exhibits44: Chart on E-commerce pharmacy - Year-over-year growth 2023-2028 (%)
Exhibits45: Data Table on E-commerce pharmacy - Year-over-year growth 2023-2028 (%)
Exhibits46: Market opportunity by Distribution Channel ($ billion)
Exhibits47: Data Table on Market opportunity by Distribution Channel ($ billion)
Exhibits48: Chart on Drug Class - Market share 2023-2028 (%)
Exhibits49: Data Table on Drug Class - Market share 2023-2028 (%)
Exhibits50: Chart on Comparison by Drug Class
Exhibits51: Data Table on Comparison by Drug Class
Exhibits52: Chart on Cholinesterase inhibitors - Market size and forecast 2023-2028 ($ billion)
Exhibits53: Data Table on Cholinesterase inhibitors - Market size and forecast 2023-2028 ($ billion)
Exhibits54: Chart on Cholinesterase inhibitors - Year-over-year growth 2023-2028 (%)
Exhibits55: Data Table on Cholinesterase inhibitors - Year-over-year growth 2023-2028 (%)
Exhibits56: Chart on N-methyl-D-aspartate receptor antagonist - Market size and forecast 2023-2028 ($ billion)
Exhibits57: Data Table on N-methyl-D-aspartate receptor antagonist - Market size and forecast 2023-2028 ($ billion)
Exhibits58: Chart on N-methyl-D-aspartate receptor antagonist - Year-over-year growth 2023-2028 (%)
Exhibits59: Data Table on N-methyl-D-aspartate receptor antagonist - Year-over-year growth 2023-2028 (%)
Exhibits60: Chart on Others - Market size and forecast 2023-2028 ($ billion)
Exhibits61: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
Exhibits62: Chart on Others - Year-over-year growth 2023-2028 (%)
Exhibits63: Data Table on Others - Year-over-year growth 2023-2028 (%)
Exhibits64: Market opportunity by Drug Class ($ billion)
Exhibits65: Data Table on Market opportunity by Drug Class ($ billion)
Exhibits66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits67: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibits68: Data Table on Market share By Geographical Landscape 2023-2028 (%)
Exhibits69: Chart on Geographic comparison
Exhibits70: Data Table on Geographic comparison
Exhibits71: Chart on North America - Market size and forecast 2023-2028 ($ billion)
Exhibits72: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
Exhibits73: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibits74: Data Table on North America - Year-over-year growth 2023-2028 (%)
Exhibits75: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibits76: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibits77: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibits78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
Exhibits79: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibits80: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibits81: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibits82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
Exhibits83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibits84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibits85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits87: Chart on US - Market size and forecast 2023-2028 ($ billion)
Exhibits88: Data Table on US - Market size and forecast 2023-2028 ($ billion)
Exhibits89: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibits90: Data Table on US - Year-over-year growth 2023-2028 (%)
Exhibits91: Chart on Canada - Market size and forecast 2023-2028 ($ billion)
Exhibits92: Data Table on Canada - Market size and forecast 2023-2028 ($ billion)
Exhibits93: Chart on Canada - Year-over-year growth 2023-2028 (%)
Exhibits94: Data Table on Canada - Year-over-year growth 2023-2028 (%)
Exhibits95: Chart on UK - Market size and forecast 2023-2028 ($ billion)
Exhibits96: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
Exhibits97: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibits98: Data Table on UK - Year-over-year growth 2023-2028 (%)
Exhibits99: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibits100: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibits101: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibits102: Data Table on Germany - Year-over-year growth 2023-2028 (%)
Exhibits103: Chart on Japan - Market size and forecast 2023-2028 ($ billion)
Exhibits104: Data Table on Japan - Market size and forecast 2023-2028 ($ billion)
Exhibits105: Chart on Japan - Year-over-year growth 2023-2028 (%)
Exhibits106: Data Table on Japan - Year-over-year growth 2023-2028 (%)
Exhibits107: Market opportunity By Geographical Landscape ($ billion)
Exhibits108: Data Tables on Market opportunity By Geographical Landscape ($ billion)
Exhibits109: Impact of drivers and challenges in 2023 and 2028
Exhibits110: Overview on Criticality of inputs and Factors of differentiation
Exhibits111: Overview on factors of disruption
Exhibits112: Impact of key risks on business
Exhibits113: Vendors covered
Exhibits114: Matrix on vendor position and classification
Exhibits115: AB Science SA - Overview
Exhibits116: AB Science SA - Product / Service
Exhibits117: AB Science SA - Key offerings
Exhibits118: AbbVie Inc. - Overview
Exhibits119: AbbVie Inc. - Product / Service
Exhibits120: AbbVie Inc. - Key news
Exhibits121: AbbVie Inc. - Key offerings
Exhibits122: AgeneBio Inc. - Overview
Exhibits123: AgeneBio Inc. - Product / Service
Exhibits124: AgeneBio Inc. - Key offerings
Exhibits125: Aurobindo Pharma Ltd. - Overview
Exhibits126: Aurobindo Pharma Ltd. - Product / Service
Exhibits127: Aurobindo Pharma Ltd. - Key offerings
Exhibits128: Cipla Ltd. - Overview
Exhibits129: Cipla Ltd. - Business segments
Exhibits130: Cipla Ltd. - Key news
Exhibits131: Cipla Ltd. - Key offerings
Exhibits132: Cipla Ltd. - Segment focus
Exhibits133: Eisai Co. Ltd. - Overview
Exhibits134: Eisai Co. Ltd. - Business segments
Exhibits135: Eisai Co. Ltd. - Key offerings
Exhibits136: Eisai Co. Ltd. - Segment focus
Exhibits137: Eli Lilly and Co. - Overview
Exhibits138: Eli Lilly and Co. - Product / Service
Exhibits139: Eli Lilly and Co. - Key news
Exhibits140: Eli Lilly and Co. - Key offerings
Exhibits141: Grifols SA - Overview
Exhibits142: Grifols SA - Business segments
Exhibits143: Grifols SA - Key offerings
Exhibits144: Grifols SA - Segment focus
Exhibits145: H Lundbeck AS - Overview
Exhibits146: H Lundbeck AS - Product / Service
Exhibits147: H Lundbeck AS - Key offerings
Exhibits148: Johnson and Johnson - Overview
Exhibits149: Johnson and Johnson - Business segments
Exhibits150: Johnson and Johnson - Key news
Exhibits151: Johnson and Johnson - Key offerings
Exhibits152: Johnson and Johnson - Segment focus
Exhibits153: Lupin Ltd. - Overview
Exhibits154: Lupin Ltd. - Product / Service
Exhibits155: Lupin Ltd. - Key news
Exhibits156: Lupin Ltd. - Key offerings
Exhibits157: Novartis AG - Overview
Exhibits158: Novartis AG - Business segments
Exhibits159: Novartis AG - Key offerings
Exhibits160: Novartis AG - Segment focus
Exhibits161: Pfizer Inc. - Overview
Exhibits162: Pfizer Inc. - Product / Service
Exhibits163: Pfizer Inc. - Key news
Exhibits164: Pfizer Inc. - Key offerings
Exhibits165: Solco Healthcare - Overview
Exhibits166: Solco Healthcare - Key offerings
Exhibits167: Teva Pharmaceutical Industries Ltd. - Overview
Exhibits168: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibits169: Teva Pharmaceutical Industries Ltd. - Key news
Exhibits170: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibits171: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibits172: Inclusions checklist
Exhibits173: Exclusions checklist
Exhibits174: Currency conversion rates for US$
Exhibits175: Research methodology
Exhibits176: Validation techniques employed for market sizing
Exhibits177: Information sources
Exhibits178: List of abbreviations